Rivoceranib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Rivoceranib
DrugBank Accession Number
DB14765
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 397.482
Monoisotopic: 397.190260381
Chemical Formula
C24H23N5O
Synonyms
  • APATINIB
  • Rivoceranib

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rivoceranib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rivoceranib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rivoceranib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Rivoceranib.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5S371K6132
CAS number
811803-05-1
InChI Key
WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
IUPAC Name
N-[4-(1-cyanocyclopentyl)phenyl]-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide
SMILES
O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1

References

General References
Not Available
ChemSpider
9490441
ChEMBL
CHEMBL3186534
ZINC
ZINC000070466461
Wikipedia
Apatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBreast Cancer / Cervical Cancers / Esophageal Neoplasms Malignant / Malignancies / Malignant Neoplasm of Stomach / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer1
4CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Relapsed and Refractory1
4Not Yet RecruitingTreatmentAdvanced Non-squamous Cell Non-small Cell Lung Cancer1
4Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach / Randomized Controlled Study1
4Not Yet RecruitingTreatmentSquamous Cell Lung Carcinoma1
4RecruitingOtherStage IV Cancer1
4Unknown StatusTreatmentNewly Diagnosed Peripheral T-cell Lymphoma1
3Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
3Active Not RecruitingTreatmentGastroesophageal Cancer (GC) / Malignant Neoplasm of Stomach1
3CompletedTreatmentAdenocarcinoma of the Stomach / Malignant Neoplasm of Stomach1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.14ALOGPS
logP4.29ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.23ChemAxon
pKa (Strongest Basic)5.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.7 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.16 m3·mol-1ChemAxon
Polarizability43.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 14:25 / Updated on February 21, 2021 18:54